SCHEMBL2715701

SCHEMBL2715701

CC(C)C(=O)Nc1cc(C(=O)NCc2ccc(OCC(F)F)c(Cl)c2)ccn1

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.60
GSK3B P49841 7/20 0.60
SCN9A Q15858 1/20 0.51
KDM1A O60341 1/20 0.44
HDAC1 Q13547 1/20 0.44
LMNA P02545 1/20 0.44
TYK2 P29597 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
WDR5 P61964 2/20 0.42
PTGES O14684 3/20 0.41
CYP3A4 P08684 1/20 0.41
AAK1 Q2M2I8 1/20 0.41
SCN3A Q9NY46 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2716439 0.91 CYP3A4 (0.48) MAPTGSK3BSCN9AKDM1AHDAC1
SCHEMBL2717172 0.90 MAPT (0.61) MAPTGSK3BSCN9AHDAC1PTGES
SCHEMBL2714487 0.89 MAPT (0.47) MAPTGSK3BSCN9AKDM1AHDAC1
SCHEMBL2715174 0.87 SCN9A (0.51) MAPTGSK3BSCN9ALMNAMEN1
SCHEMBL2713838 0.87 SCN9A (0.55) MAPTGSK3BSCN9AKDM1AHDAC1
SCHEMBL2713842 0.86 GSK3B (0.48) MAPTGSK3BTYK2
SCHEMBL2716465 0.86 SCN9A (0.61) MAPTGSK3BSCN9ALMNATYK2
SCHEMBL2717392 0.83 MAPT (0.60) MAPTGSK3BSCN9ATYK2CYP3A4
SCHEMBL2715885 0.82 MAPT (0.56) MAPTGSK3BSCN9ATYK2PTGES
SCHEMBL2716352 0.82 MAPT (0.58) MAPTGSK3BSCN9AKDM1AHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2630122-B1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2016-11-30 EP claimed
US-9302991-B2 Arylamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2016-04-05 US claimed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US claimed
EP-2630122-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RaQualia Pharma Inc (JP) 2013-08-28 EP claimed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO claimed
CN-106478497-B Arylamine derivatives as TTX-S blockers 拉夸里亚创药株式会社 2020-05-08 CN disclosed
EP-2630122-B1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2016-11-30 EP disclosed
US-9302991-B2 Arylamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2016-04-05 US disclosed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US disclosed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US disclosed
EP-2630122-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RaQualia Pharma Inc (JP) 2013-08-28 EP disclosed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO disclosed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS SCN2B, SCN1B, SCN2A MAPT 3185/4885GSK3B 4093/4885SCN9A 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.